Prior to the availability of targeted treatment with complement C5 inhibitors, the prognosis of aHUS both in pediatric and adult patients was poor—around 29% of children required dialysis or died within 1 year [4] and 48% reached chronic kidney disease (CKD) stage 5 or death at 3 years despite plasma therapy [5]. Here, C5 is linked to chronic kidney disease.